− Obtaining PRIDE Gold, the highest rating in the PRIDE Index, which evaluates companies' LGBTQ+ initiatives
− PRIDE Rainbow certification to recognize companies that promote collaboration across sectors
− Takeda's diversity, fairness & inclusiveness initiatives based on the corporate philosophy received praise

We would like to inform you that we have now obtained the highest rating “gold” for 4 consecutive years in the PRIDE Index 2024 formulated by the General Incorporated Association Work with Pride (hereafter, WwP), and received “Rainbow Certification.”
Earning gold for the fourth year in a row was evaluated for our Diversity, Equity & Inclusion (Diversity, Equity & Inclusion) (hereafter, DE&I) efforts based on our corporate philosophy.
Furthermore, we received Rainbow Certification for the first time, which recognizes companies that go beyond the scope of what can be done by our own individual efforts, collaborate with all kinds of people, and commit to realizing a workplace and society where people from sexual minorities can work in their own way.
The activities of the company and employees described below were evaluated in order to obtain PRIDE Index Gold this time and to be certified by Rainbow.
Company-related activities
In addition to programs and measures to promote LGBTQ+ inclusion, Takeda has expanded the definition of “spouse” in welfare to same-sex partners and factual marriage partners in order to meet the diverse needs of employees, and provides benefits tailored to the diverse realities of employees' lifestyles. These initiatives represent Takeda's efforts to create an environment where all employees can be themselves, and to build a work environment that understands and supports diverse work styles. It is also consistent with our promise to build an advanced organization full of diversity where each person brings out their own potential and recognizes each other's individuality.
(Main activities)

• Implementation of DE&I training for recruiters
• Consideration for entering the gender column on entry sheets at the time of employment (response items other than men and women are provided)
• Installation of universal toilets that anyone can use at the Tokyo Global Headquarters Building, Osaka Headquarters Building, and Osaka Plant
• Establishing an intranet communication window and providing information to employees
• Conduct training aimed at promoting understanding of sexual minorities such as lesbians, gays, bisexuals, and transgenders (hereafter, LGBTQ+) and sexual orientation and gender identity (hereinafter, SOGI) (hereafter, SOGI)

Employee-centered activities: Implemented by TAKE PRIDE Japan, which is part of the Takeda Employee Network (hereafter, TRG)

• We exhibited our booth at Tokyo Rainbow Pride 2024 and introduced our DE&I activities through a questionnaire to over 900 people
  The Osaka Rainbow Festival was held in October! A booth will also be exhibited in 2024, and activities aimed at fostering a better work environment through questionnaires on the work environment of the parties involved
• Industry-wide DE&I promotion activities through meetings of Pharma Ally Japan (7 companies: Bristol-Myers Squibb Co., Ltd., Japan Eli Lily Co., Ltd., Glaxo SmithKline Co., Ltd., Novartis Pharma Co., Ltd., Pfizer Inc., Takeda Pharmaceutical Co., Ltd., and Vive Healthcare Co., Ltd.), an employee network of other companies in the same industry
  “As a pharmaceutical company, we will contribute to patients and medical personnel, respect that all people live as they are, and we will work to foster that environment” with a common vision.

• DE&I promotion activities for Japanese society as a whole through employee networks including different industries (company name not disclosed)
• Introducing press articles, introducing movies, and distributing goods within the company for the purpose of promoting understanding of LGBTQ+ and SOGI

＜About TRG＞

TRG is a group where employees with their own common identities, interests, and life experiences gather and work. There are 7 TRGs active in Japan, and they aim to build communities for common purposes, provide career development and networking opportunities, and have a positive impact on business. For information on the 7 TRGs, please click here.
TAKE PRIDE Japan is a TRG that works by deepening a correct understanding of LGBTQ+ and pursuing a work environment where everyone can be themselves. Recently, TAKE PRIDE Japan has established its own consultation desk, conducted workshops based on requests from departments, and is promoting internal culture development such as developing Rainbow Carta within the company to make it easier to acquire correct knowledge.

＜About our DE&I initiatives＞

We have formulated the Global DE&I Ambition (hereafter, Ambition) * with the desire to create a rewarding work environment where everyone wants to continue working at Takeda. Furthermore, respect for human resource diversity and the creation of an inclusive work environment are also included in the four commitments set out to achieve Ambition. Belonging and building psychological safety are listed as important factors in promoting DE&I. Belonging refers to a climate where personal values and identities are recognized and respected by creating an environment where all employees, including LGBTQ+, can be themselves. Furthermore, building psychological safety is fostered by creating a fair and safe environment where employees act based on the Takeda Global Code of Conduct and the Takeda Leadership Vision, have a sense of security that they belong to and are supported by Takeda, have a sense of positive contribution to achieving goals, and can realize themselves.
* Here is a more comprehensive introduction to our efforts to respect diversity, provide fair opportunities for patients and employees in medical services and work environments, and strive to maximize their abilities by combining their abilities with the power of employees. Please check it out.

＜About Takeda Pharmaceuticals＞

Takeda Pharmaceutical Co., Ltd. (TSE:4502/NYSE:TAK) aims to contribute to the health and bright future of people around the world. We are working to create innovative pharmaceuticals in major disease areas and business fields such as digestive system/inflammatory diseases, rare diseases, plasma-fractionated preparations, oncology (cancer), neuroscience (neuropsychiatric diseases), and vaccines. Together with our partners, we are working to deliver new treatment options and contribute to improving patients' quality of life by building a strong and diverse pipeline. Takeda Pharmaceutical, headquartered in Japan, is a leading research and development biopharmaceutical company based on the value (value) of putting patients at the center based on its own corporate philosophy. Based on values that have been shaped for over 2 centuries, we are active in approximately 80 countries and regions to fulfill our raison d'être (purpose) in society.
For more information, see.

＜Important Notes＞

In this notice, “news release” means this document explained or distributed by Takeda Pharmaceutical Co., Ltd. (hereafter, “Takeda Pharmaceutical”) with respect to this news release, as well as any oral presentations, questions and answers, and written or oral materials. This news release (including oral explanations and questions and answers relating thereto) does not constitute, represent, or form part of any proposal, guidance or solicitation for the purchase, acquisition, application, exchange, sale, or other disposition of any securities in any jurisdiction, and is not intended to do so. We are not publicly offering shares or marketable securities as a result of this news release. No marketable securities will be offered in the United States, except those based on registration or registration exemption requirements under the U.S. Securities Act of 1933. This news release is provided (along with additional information provided to the recipient) under the condition that it is used by the recipient for informational purposes only (not to consider investments, acquisitions, disposal, or other transactions). Failure to comply with these restrictions may result in a violation of applicable securities laws. The companies in which Takeda Pharmaceutical directly or indirectly invests are separate companies. In this news release, the term “Takeda Pharmaceutical” may be used for convenience to refer to Takeda Pharmaceutical and its subsidiaries in general. Similarly, the term “we, us, and our company (we, our)” may also refer to subsidiaries in general or those who work for them. These terms may also be used when identifying a specific company does not provide a useful purpose. Product names mentioned in this news release are trademarks or registered trademarks of Takeda Pharmaceutical or their respective owners.

＜Future outlook information＞

This news release and materials distributed in connection with this news release include forward-looking information, philosophy, or views on Takeda Pharmaceuticals' future business, future position and performance, including Takeda Pharmaceuticals' estimates, forecasts, goals, and plans. Forward-looking information includes “targets (targets),” “plans (plans),” “believe (hopes),” “continue (hopes),” “continue (hopes),” “expect (aims),” “aim (aims),” “aim (aims),” “ensure (will),” “may (may),” and “should (should)” It often includes terms such as “would (would),” “could (could),” “anticipated (anticipated),” “anticipate (anticipated),” “anticipate (projects),” “predict (projects),” “anticipate (anticipate),” “forecast (outlook),” etc., or similar expressions or negative expressions thereof, but are not limited to that. This forward-looking information is based on assumptions relating to many important factors, and actual results may differ materially from future results expressed or implied in the forward-looking information. Key factors include the economic conditions surrounding Takeda Pharmaceuticals' global business, including general economic conditions in Japan and the United States; the emergence and development of competitor products; difficulties inherent in new product development, including changes in relevant laws and regulations, clinical success and regulatory judgments and uncertainties in the timing; uncertainties in the commercial success of new and existing products; difficulties or delays in manufacturing; fluctuations in interest rates and exchange rates; and complaints about the safety or efficacy of products or candidate products sold on the market Or concerns, the extent to which health crises such as the novel coronavirus pandemic, success of Takeda Pharmaceuticals' environmental and sustainability efforts to reduce greenhouse gas emissions or achieve other environmental goals, Takeda Pharmaceuticals' efforts to improve work efficiency, improve productivity, or reduce costs, starting with the integration of digital technology including artificial intelligence (AI), and efforts aimed at other business restructuring contribute to expected benefits, Takeda Pharmaceuticals It includes the most recent annual report on Form 20-F submitted to the US Securities and Exchange Commission, which can be viewed on the website () or at www.sec.gov, as well as other factors identified in other Takeda Pharmaceuticals' reports. Takeda is under no obligation to update any forward-looking information contained in this news release or presented by Takeda Pharmaceutical, except as required by law or stock exchange rules. Past results do not guide future management results, and Takeda Pharmaceuticals' management results and information in this news release do not indicate future management results of Takeda Pharmaceuticals, nor are they predictions, predictions, guarantees, or estimates.

1. PRIDE Index: In 2016, WWP formulated Japan's first “PRIDE Index,” an evaluation index for LGBTQ+ initiatives in the workplace. The name PRIDE aims to realize a workplace where LGBTQ+ people can work with pride, and consists of Policy (action declaration), Inspiration (enlightenment activities), Development (personnel system/program), and Engagement/Engagement (social contribution/external relations activities). See link for details